These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1020 related items for PubMed ID: 28097356

  • 1. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM.
    JAMA; 2017 Jan 10; 317(2):156-164. PubMed ID: 28097356
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
    Eidman KE, Wetmore JB.
    Semin Dial; 2018 Sep 10; 31(5):440-444. PubMed ID: 30009474
    [Abstract] [Full Text] [Related]

  • 10. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
    Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.
    Nephrol Dial Transplant; 2020 Oct 01; 35(10):1769-1778. PubMed ID: 30859218
    [Abstract] [Full Text] [Related]

  • 11. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
    Friedl C, Zitt E.
    Drug Des Devel Ther; 2018 Oct 01; 12():1589-1598. PubMed ID: 29910605
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
    Zavvos V, Fyssa L, Papasotiriou M, Papachristou E, Ntrinias T, Savvidaki E, Goumenos DS.
    Exp Clin Transplant; 2018 Jun 01; 16(3):287-293. PubMed ID: 29108515
    [Abstract] [Full Text] [Related]

  • 13. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
    Danese MD, Lubeck D, Belozeroff V, Lin TC, Desai P, Gleeson M, Martin K, Chonchol M.
    Am J Nephrol; 2020 Jun 01; 51(10):815-822. PubMed ID: 32966995
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA, Iles JN, Ariceta G, Dehmel B, Hidalgo G, Jiang X, Laskin B, Shahinfar S, Vande Walle J, Schaefer F.
    Pediatr Nephrol; 2019 Mar 01; 34(3):475-486. PubMed ID: 30506144
    [Abstract] [Full Text] [Related]

  • 15. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
    Yamada S, Tokumoto M, Taniguchi M, Toyonaga J, Suehiro T, Eriguchi R, Fujimi S, Ooboshi H, Kitazono T, Tsuruya K.
    Ther Apher Dial; 2015 Aug 01; 19(4):367-77. PubMed ID: 25851690
    [Abstract] [Full Text] [Related]

  • 16. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
    Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M.
    PLoS One; 2019 Aug 01; 14(3):e0213774. PubMed ID: 30875390
    [Abstract] [Full Text] [Related]

  • 17. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG.
    N Engl J Med; 2004 Apr 08; 350(15):1516-25. PubMed ID: 15071126
    [Abstract] [Full Text] [Related]

  • 18. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P, Vadcharavivad S, Susomboon T, Singhan W, Dumrongpisutikul N, Jakchairoongruang K, Eiam-Ong S, Praditpornsilpa K.
    Ren Fail; 2019 Nov 08; 41(1):326-333. PubMed ID: 31014177
    [Abstract] [Full Text] [Related]

  • 19. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
    Xipell M, Montagud-Marrahi E, Rubio MV, Ojeda R, Arias-Guillén M, Fontseré N, Rodas L, Vera M, Broseta JJ, Torregrosa V, Filella X, Maduell F.
    Blood Purif; 2019 Nov 08; 48(2):106-114. PubMed ID: 30699421
    [Abstract] [Full Text] [Related]

  • 20. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ.
    Kidney Int; 2003 Jan 08; 63(1):248-54. PubMed ID: 12472790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.